<DOC>
	<DOC>NCT00175851</DOC>
	<brief_summary>This is a safety and efficacy study of add-on therapy with seletracetam in epilepsy patients who have participated in a previous seletracetam study</brief_summary>
	<brief_title>Open Label Trial to Study the Long-term Safety and Efficacy of Seletracetam for the Treatment of Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<criteria>A signed and dated IRB/IEC approved written informed consent form Male/female age 18 years (16 years where permitted) to 65 years Minimum body weight of 40 kg Patients having participated in a previous seletracetam study Female patients without childbearing potential or using a medically accepted nonhormonal contraceptive method are eligible. Ongoing psychiatric disease other than mild controlled disorders Subject with clinically significant abnormalities in laboratory tests or ECG Poor compliance with visit schedule or medication intake in a previous seletracetam study Subject taking part in another clinical/pharmacological study, with the exception of seletracetam studies, in the 30 days preceding enrollment</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Partial onset, primary generalized seizures, seletracetam</keyword>
</DOC>